JP2025134747A5 - - Google Patents
Info
- Publication number
- JP2025134747A5 JP2025134747A5 JP2025095960A JP2025095960A JP2025134747A5 JP 2025134747 A5 JP2025134747 A5 JP 2025134747A5 JP 2025095960 A JP2025095960 A JP 2025095960A JP 2025095960 A JP2025095960 A JP 2025095960A JP 2025134747 A5 JP2025134747 A5 JP 2025134747A5
- Authority
- JP
- Japan
- Prior art keywords
- lou064
- patient
- use according
- pharmaceutical composition
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263314572P | 2022-02-28 | 2022-02-28 | |
| US63/314,572 | 2022-02-28 | ||
| US202263369016P | 2022-07-21 | 2022-07-21 | |
| US63/369,016 | 2022-07-21 | ||
| PCT/IB2023/051787 WO2023161887A1 (en) | 2022-02-28 | 2023-02-27 | Remibrutinib for use in the treatment of hidradenitis suppurativa |
| JP2023553381A JP7696006B2 (ja) | 2022-02-28 | 2023-02-27 | 化膿性汗腺炎の治療における使用のためのレミブルチニブ |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023553381A Division JP7696006B2 (ja) | 2022-02-28 | 2023-02-27 | 化膿性汗腺炎の治療における使用のためのレミブルチニブ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025134747A JP2025134747A (ja) | 2025-09-17 |
| JP2025134747A5 true JP2025134747A5 (https=) | 2026-03-06 |
Family
ID=85570288
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023553381A Active JP7696006B2 (ja) | 2022-02-28 | 2023-02-27 | 化膿性汗腺炎の治療における使用のためのレミブルチニブ |
| JP2025095960A Pending JP2025134747A (ja) | 2022-02-28 | 2025-06-09 | 化膿性汗腺炎の治療における使用のためのレミブルチニブ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023553381A Active JP7696006B2 (ja) | 2022-02-28 | 2023-02-27 | 化膿性汗腺炎の治療における使用のためのレミブルチニブ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250099465A1 (https=) |
| EP (1) | EP4486346A1 (https=) |
| JP (2) | JP7696006B2 (https=) |
| KR (1) | KR20240155278A (https=) |
| CN (1) | CN120617264A (https=) |
| AU (1) | AU2023225222A1 (https=) |
| CA (1) | CA3251002A1 (https=) |
| IL (1) | IL314205A (https=) |
| MX (1) | MX2024010392A (https=) |
| TW (1) | TW202342048A (https=) |
| WO (1) | WO2023161887A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250243170A1 (en) * | 2024-01-26 | 2025-07-31 | Novartis Ag | Remibrutinib drug substance and drug product substantially free of nitrosamine impurity |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| LT3380465T (lt) | 2015-11-26 | 2020-11-10 | Novartis Ag | Diamino piridino dariniai |
| JOP20190053A1 (ar) | 2016-09-23 | 2019-03-21 | Novartis Ag | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |
| JP7007374B2 (ja) | 2016-09-23 | 2022-01-24 | ノバルティス アーゲー | 腱及び／又は靭帯損傷に使用するためのインダゾール化合物 |
| CN112512527A (zh) * | 2018-09-12 | 2021-03-16 | 杭州索元生物医药股份有限公司 | 恩扎妥林和btk抑制剂的组合及其用途 |
| MX2021014161A (es) | 2019-05-23 | 2022-01-04 | Novartis Ag | Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. |
| HRP20251001T1 (hr) | 2019-05-23 | 2025-10-24 | Novartis Ag | Inhibitor brutonove tirozin kinaze za upotrebu u liječenju kronične spontane urtikarije |
| BR112021023054A2 (pt) * | 2019-05-23 | 2022-03-29 | Novartis Ag | Formas cristalinas de um inibidor de btk |
| TW202142237A (zh) * | 2020-01-08 | 2021-11-16 | 美商普林斯匹亞生物製藥公司 | 包含2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)-1h-吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4,4-二甲基戊-2-烯腈之局部醫藥組成物 |
| TWI905371B (zh) | 2021-01-26 | 2025-11-21 | 瑞士商諾華公司 | 藥物組成物 |
-
2023
- 2023-02-24 TW TW112107010A patent/TW202342048A/zh unknown
- 2023-02-27 IL IL314205A patent/IL314205A/en unknown
- 2023-02-27 US US18/729,542 patent/US20250099465A1/en active Pending
- 2023-02-27 KR KR1020247031567A patent/KR20240155278A/ko active Pending
- 2023-02-27 EP EP23710457.5A patent/EP4486346A1/en active Pending
- 2023-02-27 AU AU2023225222A patent/AU2023225222A1/en active Pending
- 2023-02-27 WO PCT/IB2023/051787 patent/WO2023161887A1/en not_active Ceased
- 2023-02-27 CA CA3251002A patent/CA3251002A1/en active Pending
- 2023-02-27 JP JP2023553381A patent/JP7696006B2/ja active Active
- 2023-02-27 MX MX2024010392A patent/MX2024010392A/es unknown
- 2023-02-27 CN CN202511059211.7A patent/CN120617264A/zh active Pending
-
2025
- 2025-06-09 JP JP2025095960A patent/JP2025134747A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5715101B2 (ja) | ピルフェニドンおよび薬学的に受容可能な賦形剤のカプセル処方物 | |
| TW202116303A (zh) | α—１抗胰蛋白酶缺乏症之治療方法 | |
| JP2025134747A5 (https=) | ||
| JP2024178420A5 (https=) | ||
| CN111012785A (zh) | 喹啉衍生物用于治疗甲状腺癌的方法和用途 | |
| JP7701757B2 (ja) | タウロデオキシコール酸またはその薬学的に許容される塩を有効成分として含む新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の治療用組成物 | |
| CA2442410A1 (en) | Duloxetine for treatment of hot flashes | |
| JP2003525899A (ja) | 乾癬の治療 | |
| EP3616697A1 (en) | Use of a pharmaceutical carrier in the preparation of an anti-diabetic pharmaceutical composition | |
| JP2004091473A (ja) | 色素沈着改善治療薬 | |
| WO2008057464A2 (en) | Compositions and methods for improving the bioavailability of liothyronine | |
| TW200951117A (en) | Combination of dronedarone with at least one diuretic, therapeutic application thereof | |
| JP2018528238A (ja) | 円形脱毛症の治療 | |
| JP6959478B1 (ja) | ポルフィリン症の予防又は治療剤 | |
| WO2014131360A1 (zh) | 普罗布考及其衍生物抗肿瘤转移的用途 | |
| US20040152733A1 (en) | Duloxetine for treatment of hot flashes | |
| JP2025506869A (ja) | 特発性肺線維症の処置のための組成物及び方法 | |
| EP3766496B1 (en) | Anlotinib for treatment of nasopharyngeal carcinoma | |
| JP2023503844A (ja) | 乾癬を治療する漢方薬組成物、その製造方法及び使用 | |
| WO2023220396A1 (en) | Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor | |
| CN110664799B (zh) | 用于治疗脑缺血的药物组合物及其应用 | |
| JPH10175852A5 (https=) | ||
| CN112826820B (zh) | Nlrp3抑制剂及其应用 | |
| CN111035763A (zh) | 一种治疗妇女更年期综合症的药物组合物 | |
| TW202214249A (zh) | 紫質症之預防或治療劑 |